Diabetic Gastroparesis Treatment Market, By Product Type (Drugs (Gastroprokinetic Agents, Antiemetic Agents, Botulinum Toxin), Surgical Treatment Products (Gastric Electrical Stimulation (GES) Device, Percutaneous Endoscopic Gastrostomy (PEG) Kit, Parenteral Nutrition)), By Disease Indication (Compensated Gastroparesis, Gastric Failure), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : May 2023

Code : CMI3603

Pages :170

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Diabetic Gastroparesis Treatment Market : Key Developments

For instance, in July 2020, the U.S. Food and Drug Administration (FDA) approved the use of tradipitant, a product of Vanda Pharmaceuticals, a U.S.-based biopharmaceutical company, for up to 6 months with an option of renewal for an individual patient who requested expanded access of drug for the treatment of gastroparesis

In July 15, 2020, Evoke Pharma, U.S. based pharmaceutical company Initiated Commercial Manufacturing of Gimoti after it got U.S. Food and Drug Administration approval for the same in June 2020. Gimoti is a nasal spray used to treat diabetic gastroparesis, a complication of diabetes where the stomach's digestion slows down. The company along with Patheon, a U.S.-based commercial manufacturing company has started manufacturing process and planned to launch the product by fourth quarter of 2020.

In March, 2021, Johns Hopkins Medicine conducted a clinical trial on Gastric per-oral Endoscopic Myotomy for the treatment of for the management of refractory gastroparesis . The G-POEM procedure was determined to be safe, although its overall efficacy in treating refractory gastroparesis was moderate.

In April 9, 2022, according to study published in Iranian Journal of Basic Medical Sciences, Atractylodes chinensis volatile oil can be used to treat diabetic gastroparesis. The animal study was carried out where Atractylodes chinensis volatile oil effectively promoted gastric emptying and intestinal propulsion in the diabetic gastroparesis rats and increased gastric acid secretion. Furthermore, after the treatment of Atractylodes chinensis volatile oil, the serum insulin like growth factor-1 level in diabetic gastroparesis rats was increased. The morphology and arrangement of the cells and the number of interstitial cell of cajal in the gastric tissue were restored. Hence it was concluded that Atractylodes chinensis volatile oil plays a positive role in the treatment of diabetic gastroparesis.